AXLRx Book a callCommission

Rare Disease · GCC (Gulf) · In-Market

GCC PNH KOL Mapping

Seven institutions across Riyadh, Jeddah, Dubai and Abu Dhabi hold the GCC's confirmed PNH caseload. Just 5 to 8 physicians function as genuine adoption gatekeepers. That kind of concentration is exactly what this workbook sizes before any individual name enters it.

Assess this report See what's inside ↓ Reviewed by Mark W, Commercial Analyst Last updated August 2026
Market United Kingdom France GCC (Gulf) Stage

Key takeaways

  • 7 specialist institutions across Riyadh, Jeddah, and Dubai/Abu Dhabi concentrating confirmed GCC PNH management
  • ~40 patients in the KFSH&RC Riyadh PNH cohort, the largest published case series in the GCC
  • <10 haematologists across the GCC network managing confirmed PNH cases
  • 5-8 physicians who function as genuine adoption gatekeepers for a new complement inhibitor entering the GCC

Fewer than 10 GCC haematologists, concentrated at seven institutions across three cities, manage the region's confirmed PNH caseload, and 5-8 of them decide whether a new agent gets adopted.

GCC PNH expertise concentrates around a small number of specialist centres, not a broad regional field. Confirmed PNH management sits at seven institutions across three cities: King Faisal Specialist Hospital & Research Centre (KFSH&RC) in Riyadh, which anchors the region's largest published PNH cohort at roughly 40 patients, King Abdulaziz Medical City (KAMC) in both Riyadh and Jeddah, American Hospital Dubai, Rashid Hospital in Dubai, and Sheikh Shakhbout Medical City together with AUH in Abu Dhabi. Fewer than 10 haematologists across this network manage the confirmed GCC PNH caseload, itself only around 400 of an estimated 2,000 to 3,000 patient pool given the region's FLAER-testing bottleneck. That concentration is not incidental; NPHC's prior-authorisation criteria route every confirmed diagnosis through these same institutions. Our KOL Universe gate (K1) starts by mapping exactly this seven-institution structure before any single physician is scored.

That structure changes how AXLRx tiers influence in the GCC. A haematologist at KFSH&RC, the region's largest published cohort and the institution most likely to shape NPHC's own prior-authorisation posture, carries different scientific weight than one at a lower-volume peripheral centre, and our Tier Classification gate (K2) scores that distinction directly. Only 5 to 8 physicians across this network function as genuine adoption gatekeepers, the practitioners whose prescribing decisions determine whether a new complement inhibitor gains real GCC uptake once SFDA registration clears. No named individual enters the workbook without a verification tag. Every KOL identity is checked against live publication records and institutional affiliations, then marked Verified, Industry benchmark, or Requires client validation.

The GCC PNH institution network, seven centres across three cities

GCC CENTRE STRUCTURE
InstitutionCityRole in Network
King Faisal Specialist Hospital & Research Centre (KFSH&RC)RiyadhAnchor referral centre; largest published GCC PNH cohort (~40 patients)
King Abdulaziz Medical City (KAMC)RiyadhNPHC-designated haematology centre
King Abdulaziz Medical City (KAMC)JeddahNPHC-designated haematology centre
American Hospital DubaiDubaiDesignated treatment centre
Rashid HospitalDubaiDesignated treatment centre
Sheikh Shakhbout Medical CityAbu DhabiDesignated treatment centre
AUHAbu DhabiDesignated treatment centre

Sources: NPHC Pharmaceutical Benefits Committee review process documentation; KFSH&RC haematology department published case series 2019-2023; SNRHD 2022; GCC haematology society PNH case registry.

What this workbook answers

Every section answers a named commercial question your team is asking, scoped to your asset.

  1. Which GCC institutions actually concentrate confirmed PNH management, and how few physicians sit behind that network? • The seven-institution structure across Riyadh, Jeddah, Dubai, and Abu Dhabi • physician concentration as a KOL-tiering signal • K1 KOL Universe Sizing methodology
  2. How does AXLRx identify the 5 to 8 physicians who actually decide GCC adoption of a new complement inhibitor? • K2 Tier Classification methodology • KFSH&RC cohort authorship and NPHC prior-authorisation-role weighting • K3 Scientific Influence scoring inputs
  3. What verification standard does every named KOL have to clear before shipping in the workbook? • The three-tag verification protocol (Verified/Industry benchmark/Requires client validation) • live publication and institutional-affiliation cross-checks • why no placeholder name ships unflagged
What's inside

Rare Disease · 24–32 pp · In-Market · Analyst report + Excel model + PowerPoint readout

  1. 1 · The Binding Constraint 2 pp
    • Why institutional concentration, not scattergun individual outreach, is the single variable this workbook sizes first
    • Pressure-tested against the seven-institution GCC network case before the rest of the workbook is built out
  2. 2 · KOL Universe (K1) 4 pp
    • Every GCC PNH KOL sized and sourced from publication and institutional-affiliation data
    • The seven-institution network across Riyadh, Jeddah, Dubai, and Abu Dhabi as the sizing anchor
    • Universe boundaries: who counts as a KOL versus a high-volume prescriber
  3. 3 · Tier Classification (K2) 3 pp
    • Scientific-influence scoring across KFSH&RC cohort authorship and NPHC prior-authorisation role
    • What separates a Tier 1 KOL from a high-volume community prescriber
  4. 4 · Scientific Influence (K3) 3 pp
    • Influence inputs: published cohort authorship, NPHC-facing institutional role, FLAER-testing capability
    • Cross-checked against independent publication and citation data
  5. 5 · Engagement Readiness (K4) 3 pp
    • Readiness scoring and channel recommendations per KOL
    • Sequencing implications for MSL deployment
  6. 6 · MSL Territory Coverage (K5) 3 pp
    • Territory-to-KOL coverage map across Riyadh, Jeddah, Dubai, and Abu Dhabi
    • Where current MSL deployment has gaps across the remaining GCC states
  7. 7 · Cross-Border Network (K6) 3 pp
    • Multi-market reach for KOLs active beyond Saudi Arabia, across the wider GCC
    • Implications for coordinated versus purely local engagement
  8. 8 · Client Alignment Questions 2 pp
    • The open KOL-engagement questions your medical affairs team must close
    • Structured for an internal alignment session before MSL deployment

Appendix and source ledger included · 45-minute analyst readout included with delivery

Custom workbook delivered in 72 hours.

Assess this report

Included with every brief

PDF
PDF Brief
KOL Mapping Brief — Summary Edition
PDF summary brief: tier strip, KOL universe table, and geographic breakdown for GCC PNH.
XLS
Excel Model
KOL Mapping Workbook — Excel
6-sheet editable workbook: KOL Universe, Tier Scoring, Engagement Calendar, MSL Territory, Cross-Border Network, Evidence Register.

Get Started

Commission this workbook

AXLRx delivers KOL mapping workbooks built for medical affairs and commercial teams engaging GCC PNH specialists. Custom workbook in 72 hours.

  1. 1. Submit your requestSpecify your indication, geography, and institution scope.
  2. 2. Scoping callAXLRx analyst confirms institution scope and verification standard before building.
  3. 3. DeliveryResearch-verified KOL workbook in 72 hours with optional analyst readout.
Assess this report View sample workbooks

How AXLRx builds this workbook

Prepared by MoatRx analysts on the AXLRx commercial consulting engine.

Every AXLRx KOL workbook is built from live publication records and institutional-affiliation data, not secondary summaries. No KOL name ships without a verification tag.

GCC PNH KOL sources: KFSH&RC haematology department published case series; NPHC Pharmaceutical Benefits Committee review process documentation; SNRHD 2022; and the institutional affiliations named in those publications.

  • Institution list and KFSH&RC cohort size verified against KFSH&RC haematology department published case series 2019-2023
  • Confirmed-case and haematologist-concentration figures verified against SNRHD 2022 and NPHC Pharmaceutical Benefits Committee documentation
  • Every KOL entry in the underlying workbook carries a three-tag verification status before delivery: Verified, Industry benchmark, or Requires client validation

Frequently asked questions

Deliverables What formats are included with every workbook?

Every commissioned KOL Mapping workbook includes an editable 6-sheet Excel workbook (KOL Universe, Tier Scoring, Engagement Calendar, MSL Territory, Cross-Border Network, Evidence Register) and a PDF summary brief. No PowerPoint deck: this deliverable is built to be worked in directly. An optional 45-minute analyst readout call is included.

Sources How are KOL identities and rankings verified?

Every KOL entry is built from published haematology case series, NPHC Pharmaceutical Benefits Committee review documentation, and the institutional affiliations named in them, then tagged Verified, Industry benchmark, or Requires client validation. No name ships unverified.

Customisation Can I scope this to a specific GCC state or named-centre set?

Yes. The intake form captures your indication, geography, and institution scope. A scoping call confirms scope before research starts. Commission via the intake form to start.